Cargando…
GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation
AIMS: To determine whether the Global Anticoagulant Registry in the FIELD–Atrial Fibrillation (GARFIELD-AF) integrated risk tool predicts mortality, non-haemorrhagic stroke/systemic embolism, and major bleeding for up to 2 years after new-onset AF and to assess how this risk tool performs compared w...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888127/ https://www.ncbi.nlm.nih.gov/pubmed/33892489 http://dx.doi.org/10.1093/ehjqcco/qcab028 |
_version_ | 1784661065806643200 |
---|---|
author | Fox, Keith A A Virdone, Saverio Pieper, Karen S Bassand, Jean-Pierre Camm, A John Fitzmaurice, David A Goldhaber, Samuel Z Goto, Shinya Haas, Sylvia Kayani, Gloria Oto, Ali Misselwitz, Frank Piccini, Jonathan P Dalgaard, Frederik Turpie, Alexander G G Verheugt, Freek W A Kakkar, Ajay K |
author_facet | Fox, Keith A A Virdone, Saverio Pieper, Karen S Bassand, Jean-Pierre Camm, A John Fitzmaurice, David A Goldhaber, Samuel Z Goto, Shinya Haas, Sylvia Kayani, Gloria Oto, Ali Misselwitz, Frank Piccini, Jonathan P Dalgaard, Frederik Turpie, Alexander G G Verheugt, Freek W A Kakkar, Ajay K |
author_sort | Fox, Keith A A |
collection | PubMed |
description | AIMS: To determine whether the Global Anticoagulant Registry in the FIELD–Atrial Fibrillation (GARFIELD-AF) integrated risk tool predicts mortality, non-haemorrhagic stroke/systemic embolism, and major bleeding for up to 2 years after new-onset AF and to assess how this risk tool performs compared with CHA(2)DS(2)-VASc and HAS-BLED. METHODS AND RESULTS: Potential predictors of events included demographic and clinical characteristics, choice of treatment, and lifestyle factors. A Cox proportional hazards model was identified for each outcome by least absolute shrinkage and selection operator methods. Indices were evaluated in comparison with CHA(2)DS(2)-VASc and HAS-BLED risk predictors. Models were validated internally and externally in ORBIT-AF and Danish nationwide registries. Among the 52 080 patients enrolled in GARFIELD-AF, 52 032 had follow-up data. The GARFIELD-AF risk tool outperformed CHA(2)DS(2)-VASc for all-cause mortality in all cohorts. The GARFIELD-AF risk score was superior to CHA(2)DS(2)-VASc for non-haemorrhagic stroke, and it outperformed HAS-BLED for major bleeding in internal validation and in the Danish AF cohort. In very low- to low-risk patients [CHA(2)DS(2)-VASc 0 or 1 (men) and 1 or 2 (women)], the GARFIELD-AF risk score offered strong discriminatory value for all the endpoints when compared to CHA(2)DS(2)-VASc and HAS-BLED. The GARFIELD-AF tool also included the effect of oral anticoagulation (OAC) therapy, thus allowing clinicians to compare the expected outcome of different anticoagulant treatment decisions [i.e. no OAC, non-vitamin K antagonist (VKA) oral anticoagulants, or VKAs]. CONCLUSIONS: The GARFIELD-AF risk tool outperformed CHA(2)DS(2)-VASc at predicting death and non-haemorrhagic stroke, and it outperformed HAS-BLED for major bleeding in overall as well as in very low- to low-risk group patients with AF. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF: NCT01090362, ORBIT-AF I: NCT01165710; ORBIT-AF II: NCT01701817. |
format | Online Article Text |
id | pubmed-8888127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-88881272022-03-02 GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation Fox, Keith A A Virdone, Saverio Pieper, Karen S Bassand, Jean-Pierre Camm, A John Fitzmaurice, David A Goldhaber, Samuel Z Goto, Shinya Haas, Sylvia Kayani, Gloria Oto, Ali Misselwitz, Frank Piccini, Jonathan P Dalgaard, Frederik Turpie, Alexander G G Verheugt, Freek W A Kakkar, Ajay K Eur Heart J Qual Care Clin Outcomes Original Article AIMS: To determine whether the Global Anticoagulant Registry in the FIELD–Atrial Fibrillation (GARFIELD-AF) integrated risk tool predicts mortality, non-haemorrhagic stroke/systemic embolism, and major bleeding for up to 2 years after new-onset AF and to assess how this risk tool performs compared with CHA(2)DS(2)-VASc and HAS-BLED. METHODS AND RESULTS: Potential predictors of events included demographic and clinical characteristics, choice of treatment, and lifestyle factors. A Cox proportional hazards model was identified for each outcome by least absolute shrinkage and selection operator methods. Indices were evaluated in comparison with CHA(2)DS(2)-VASc and HAS-BLED risk predictors. Models were validated internally and externally in ORBIT-AF and Danish nationwide registries. Among the 52 080 patients enrolled in GARFIELD-AF, 52 032 had follow-up data. The GARFIELD-AF risk tool outperformed CHA(2)DS(2)-VASc for all-cause mortality in all cohorts. The GARFIELD-AF risk score was superior to CHA(2)DS(2)-VASc for non-haemorrhagic stroke, and it outperformed HAS-BLED for major bleeding in internal validation and in the Danish AF cohort. In very low- to low-risk patients [CHA(2)DS(2)-VASc 0 or 1 (men) and 1 or 2 (women)], the GARFIELD-AF risk score offered strong discriminatory value for all the endpoints when compared to CHA(2)DS(2)-VASc and HAS-BLED. The GARFIELD-AF tool also included the effect of oral anticoagulation (OAC) therapy, thus allowing clinicians to compare the expected outcome of different anticoagulant treatment decisions [i.e. no OAC, non-vitamin K antagonist (VKA) oral anticoagulants, or VKAs]. CONCLUSIONS: The GARFIELD-AF risk tool outperformed CHA(2)DS(2)-VASc at predicting death and non-haemorrhagic stroke, and it outperformed HAS-BLED for major bleeding in overall as well as in very low- to low-risk group patients with AF. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF: NCT01090362, ORBIT-AF I: NCT01165710; ORBIT-AF II: NCT01701817. Oxford University Press 2021-05-25 /pmc/articles/PMC8888127/ /pubmed/33892489 http://dx.doi.org/10.1093/ehjqcco/qcab028 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Article Fox, Keith A A Virdone, Saverio Pieper, Karen S Bassand, Jean-Pierre Camm, A John Fitzmaurice, David A Goldhaber, Samuel Z Goto, Shinya Haas, Sylvia Kayani, Gloria Oto, Ali Misselwitz, Frank Piccini, Jonathan P Dalgaard, Frederik Turpie, Alexander G G Verheugt, Freek W A Kakkar, Ajay K GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation |
title | GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation |
title_full | GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation |
title_fullStr | GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation |
title_full_unstemmed | GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation |
title_short | GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation |
title_sort | garfield-af risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888127/ https://www.ncbi.nlm.nih.gov/pubmed/33892489 http://dx.doi.org/10.1093/ehjqcco/qcab028 |
work_keys_str_mv | AT foxkeithaa garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation AT virdonesaverio garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation AT pieperkarens garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation AT bassandjeanpierre garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation AT cammajohn garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation AT fitzmauricedavida garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation AT goldhabersamuelz garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation AT gotoshinya garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation AT haassylvia garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation AT kayanigloria garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation AT otoali garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation AT misselwitzfrank garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation AT piccinijonathanp garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation AT dalgaardfrederik garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation AT turpiealexandergg garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation AT verheugtfreekwa garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation AT kakkarajayk garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation AT garfieldafriskscoreformortalitystrokeandbleedingwithin2yearsinpatientswithatrialfibrillation |